Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
Male
Humans
Prevalence
Cohort Studies
Homosexuality, Male
Hepatitis C, Chronic
/ drug therapy
Antiviral Agents
/ therapeutic use
Switzerland
/ epidemiology
Drug Users
HIV Infections
/ drug therapy
Substance Abuse, Intravenous
/ complications
Sexual and Gender Minorities
Hepatitis C
/ drug therapy
Hepacivirus
/ genetics
Coinfection
/ drug therapy
RNA
DAA
HCV
HIV
HIV coinfection
hepatitis C
hepatitis C treatment outcomes
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
01 2024
01 2024
Historique:
revised:
15
09
2023
received:
06
07
2023
accepted:
19
09
2023
medline:
20
12
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver-related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study. We included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver-related mortality, as well as the yearly incidence of liver-related events in persons with at least one documented positive HCV-RNA. Of 14 652 participants under follow-up, 2294 had at least one positive HCV-RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient-years (PY) to 1.1 per 100 PY, and incidence of liver-related events decreased from 1.4/100 PY to 0.2/100 PY. The introduction of DAA therapy was associated with a more than 10-fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver-related events declined substantially in persons living with HIV and hepatitis C.
Sections du résumé
BACKGROUND AND AIMS
Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver-related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study.
METHODS
We included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver-related mortality, as well as the yearly incidence of liver-related events in persons with at least one documented positive HCV-RNA.
RESULTS
Of 14 652 participants under follow-up, 2294 had at least one positive HCV-RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient-years (PY) to 1.1 per 100 PY, and incidence of liver-related events decreased from 1.4/100 PY to 0.2/100 PY.
CONCLUSIONS
The introduction of DAA therapy was associated with a more than 10-fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver-related events declined substantially in persons living with HIV and hepatitis C.
Substances chimiques
Antiviral Agents
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-179Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Informations de copyright
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-569. doi:10.1086/321909
Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632. doi:10.1001/archinte.166.15.1632
World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016-2021: Actions for Impact: Web Annex 1: Key Data at a Glance. World Health Organization; 2021. Accessed December 1, 2022. https://apps.who.int/iris/handle/10665/342808
Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797-808. doi:10.1016/S1473-3099(15)00485-5
Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022;19(8):533-550. doi:10.1038/s41575-022-00608-8
Amele S, Peters L, Rodger A, et al. Effectiveness and safety of interferon-free direct-acting antiviral hepatitis C virus therapy in HIV/hepatitis C virus coinfected individuals: results from a pan-European study. J Acquir Immune Defic Syndr. 2021;86(2):248-257. doi:10.1097/QAI.0000000000002541
Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125-133. doi:10.1016/S2468-1253(17)30284-4
Mohamed R, Cordie A, Lazarus JV, Esmat G. Micro-elimination of hepatitis C among people living with HIV in Egypt. Liver Int. 2021;41(7):1445-1447. doi:10.1111/liv.14974
Fursa O, Mocroft A, Lazarus JV, et al. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences. AIDS. 2022;36(3):423-435. doi:10.1097/QAD.0000000000003112
Kovari H, Ledergerber B, Cavassini M, et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. J Hepatol. 2015;63(3):573-580. doi:10.1016/j.jhep.2015.04.019
Bundesamt für Gesundheit-BAG. Sovaldi Limitationsänderungen 01.09.2015-2.pdf. Published online September 1, 2015. Accessed February 11, 2023. https://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/Arzneimittel/Beurteilungen-BAG-von-Arzneimitteln-der-Spezialitaetenliste.html
Bundesamt für Gesundheit-BAG. Erweiterte Vergütung bestimmter Arzneimittel gegen Hepatitis C.pdf. Published online July 27, 2015. Accessed February 11, 2023. https://www.admin.ch/gov/de/start/dokumentation/medienmitteilungen.msg-id-58174.html
Bundesamt für Gesundheit-BAG. Medienmitteilung-BAG erweitert Vergütung von Medikamenten gegen Hepatitis C. Published online April 27, 2017. Accessed February 11, 2023. https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/medienmitteilungen.msg-id-66508.html
Braun DL, Hampel B, Ledergerber B, et al. A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV cohort study. Clin Infect Dis. 2021;73(7):e2194-e2202. doi:10.1093/cid/ciaa1124
Salazar-Vizcaya L, Wandeler G, Fehr J, et al. Impact of direct-acting antivirals on the burden of HCV infection among persons who inject drugs and men who have sex with men in the Swiss HIV cohort study. Open Forum Infect Dis. 2018;5(7):ofy154. doi:10.1093/ofid/ofy154
Scherrer AU, Traytel A, Braun DL, et al. Cohort profile update: the Swiss HIV cohort study (SHCS). Int J Epidemiol. 2022;51(1):33-34j. doi:10.1093/ije/dyab141
EACS. Guidelines version 11.1, October 2022. https://www.eacsociety.org/guidelines/eacs-guidelines/
Bundesamt für Gesundheit-BAG. BAG Bulletin 33/14. Published online August 11, 2014.
Bundesamt für Gesundheit-BAG. Befristete Neuaufnahme in die Spezialitätenliste (SL) per 01. September 2019. Published online September 1, 2023.
Richard JL, Schaetti C, Basler S, Musezahl M. The epidemiology of hepatitis C in Switzerland: trends in notifications, 1988-2015. Swiss Med Wkly. 1970;148:w14619. doi:10.4414/smw.2018.14619
Fanciulli C, Berenguer J, Busca C, et al. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV Med. 2022;23(7):705-716. doi:10.1111/hiv.13229
Isfordink CJ, Smit C, Boyd A, et al. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands. AIDS. 2022;36(6):773-783. doi:10.1097/QAD.0000000000003159
Peters L, Laut K, Resnati C, et al. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018;32(14):1995-2004. doi:10.1097/QAD.0000000000001928
Saeed S, Strumpf E, Moodie EEM, et al. Eliminating structural barriers: the impact of unrestricted access on hepatitis C treatment uptake among people living with human immunodeficiency virus. Clin Infect Dis. 2020;71(2):363-371. doi:10.1093/cid/ciz833
Thompson WW, Symum H, Sandul A, et al. Vital signs: hepatitis C treatment among insured adults-United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022;71(32):1011-1017. doi:10.15585/mmwr.mm7132e1
Falade-Nwulia O, Sutcliffe CG, Mehta SH, et al. Hepatitis C elimination in people with HIV is contingent on closing gaps in the HIV continuum. Open Forum Infect Dis. 2019;6(10):ofz426. doi:10.1093/ofid/ofz426
Smit C, Boyd A, Rijnders BJA, et al. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. The Lancet HIV. 2021;8(2):e96-e105. doi:10.1016/S2352-3018(20)30301-5
Kusejko K, Salazar-Vizcaya L, Shah C, et al. Sustained effect on hepatitis C elimination among men who have sex with men in the Swiss HIV cohort study: a systematic re-screening for hepatitis C RNA two years following a nation-wide elimination program. Clin Infect Dis. 2022;75(10):1723-1731. doi:10.1093/cid/ciac273
Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66(9):1360-1365. doi:10.1093/cid/cix1007
van Santen DK, Sacks-Davis R, Stewart A, et al. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019. eClinicalMedicine. 2023;56:101810. doi:10.1016/j.eclinm.2022.101810
Breskin A, Westreich D, Cole SR, et al. The effects of hepatitis C infection and treatment on all-cause mortality among people living with human immunodeficiency virus. Clin Infect Dis. 2019;68(7):1152-1159.
Yin X, Kong L, Du P, Jung J. Effects of direct-acting antiviral treatment on reducing mortality among medicare beneficiaries with HIV and HCV coinfection. AIDS Care. 2022;34(10):1330-1337. doi:10.1080/09540121.2021.1981221
Chalouni M, Trickey A, Ingle SM, et al. Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after ART initiation. AIDS. 2023;37(10):1573-1581. doi:10.1097/QAD.0000000000003594
Ogawa E, Chien N, Kam L, et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. JAMA Intern Med. 2022;12:97-105. doi:10.1001/jamainternmed.2022.5699
Cepeda JA, Thomas DL, Astemborski J, et al. Impact of hepatitis C treatment uptake on cirrhosis and mortality in persons who inject drugs: a longitudinal, community-based cohort study. Ann Intern Med. 2022;175(8):1083-1091. doi:10.7326/M21-3846
Janjua NZ, Wong S, Abdia Y, et al. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol. 2021;75(5):1049-1057. doi:10.1016/j.jhep.2021.05.028
Lombardi A, Mondelli MU. Hepatitis C: is eradication possible? Liver Int. 2019;39(3):416-426. doi:10.1111/liv.14011
Béguelin C, Suter A, Bernasconi E, et al. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the swiss HIV cohort study. Liver Int. 2018;38(3):424-431. doi:10.1111/liv.13528
Rauch A, Gaudieri S, Evison J, et al. Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the swiss HIV cohort study. Antivir Ther. 2008;13(3):455-460.